Eficiencia de un tratamiento de duración fija con Venetoclax en combinación con Rituximab en pacientes con Leucemia Linfocítica Crónica (LLC)

  1. Raúl Ferrando 1
  2. Eduardo Ríos 2
  3. José Luis Sastre 3
  4. Áurea Gómez 3
  5. María Echave 4
  6. Manuel Gómez Barrera 4
  7. Itziar Oyagüez 4
  8. Julia Salvador 5
  9. Raquel Sánchez 5
  1. 1 Hospital General de Castellón
    info

    Hospital General de Castellón

    Castelló de la Plana, España

    ROR https://ror.org/02yp1e416

  2. 2 Hospital Universitario de Valme
    info

    Hospital Universitario de Valme

    Sevilla, España

    ROR https://ror.org/04cxs7048

  3. 3 Hospital Universitario de Ourense
  4. 4 Pharmacoeconomics and Outcomes Research Iberia
    info

    Pharmacoeconomics and Outcomes Research Iberia

    Pozuelo de Alarcón, España

  5. 5 AbbVie Spain
Show affiliations +
Journal:
Actualidad en farmacología y terapéutica

ISSN: 1698-4277

Year of publication: 2021

Volume: 19

Issue: 2

Pages: 78-87

Type: Article

DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Actualidad en farmacología y terapéutica

Abstract

This work presents a review on the efficiency of a fixed-duration treatment with venetoclax (BCL-2 inhibitor) in combination with rituximab, as therapy for patients with chronic lymphocytic leukemia. Venetoclax in combination with rituximab has shown high response rates and minimal residual disease in patients with relapsed or refractory chronic lymphocytic leukemia; the fixed duration of venetoclax in combination makes it also in a predictable cost option that generates savings versus alternatives to progression, contributing thus to the sustainability of the health system.

Data source: Dialnet